DO & CO Toekomstige groei

Future criteriumcontroles 4/6

DO & CO zal naar verwachting groeien in winst en omzet met respectievelijk 18.4% en 6.8% per jaar. De winst per aandeel zal naar verwachting groeien met 17.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 23.9% zijn.

Belangrijke informatie

18.4%

Groei van de winst

17.4%

Groei van de winst per aandeel

Commercial Services winstgroei	16.5%
Inkomstengroei	6.8%
Toekomstig rendement op eigen vermogen	23.9%
Dekking van analisten	Low
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Earnings Update: DO & CO Aktiengesellschaft (VIE:DOC) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Jun 30

Recent updates

Earnings Update: DO & CO Aktiengesellschaft (VIE:DOC) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Jun 30

DO & CO (VIE:DOC) Could Easily Take On More Debt

Jun 28

DO & CO (VIE:DOC) Shareholders Will Want The ROCE Trajectory To Continue

May 30

At €149, Is DO & CO Aktiengesellschaft (VIE:DOC) Worth Looking At Closely?

May 13

DO & CO (VIE:DOC) Could Easily Take On More Debt

Mar 07

We Think DO & CO's (VIE:DOC) Robust Earnings Are Conservative

Feb 22

Shareholders Should Be Pleased With DO & CO Aktiengesellschaft's (VIE:DOC) Price

Feb 05

At €133, Is It Time To Put DO & CO Aktiengesellschaft (VIE:DOC) On Your Watch List?

Dec 26

Is There An Opportunity With DO & CO Aktiengesellschaft's (VIE:DOC) 48% Undervaluation?

Nov 17

The Returns At DO & CO (VIE:DOC) Aren't Growing

Oct 13

DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet

Sep 19

At €119, Is It Time To Put DO & CO Aktiengesellschaft (VIE:DOC) On Your Watch List?

Jul 27

Returns On Capital At DO & CO (VIE:DOC) Have Stalled

Jun 30

Is DO & CO Aktiengesellschaft (VIE:DOC) Trading At A 42% Discount?

Jun 17

Is It Time To Consider Buying DO & CO Aktiengesellschaft (VIE:DOC)?

Apr 03

An Intrinsic Calculation For DO & CO Aktiengesellschaft (VIE:DOC) Suggests It's 38% Undervalued

Mar 16

DO & CO's (VIE:DOC) Returns On Capital Not Reflecting Well On The Business

Oct 18

DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet

Sep 24

Is There Now An Opportunity In DO & CO Aktiengesellschaft (VIE:DOC)?

Aug 25

Does DO & CO (VIE:DOC) Have A Healthy Balance Sheet?

May 11

Returns On Capital At DO & CO (VIE:DOC) Paint A Concerning Picture

Mar 26

DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet

Feb 09

Why DO & CO's (VIE:DOC) Earnings Are Better Than They Seem

Nov 25

Capital Allocation Trends At DO & CO (VIE:DOC) Aren't Ideal

Nov 09

Does DO & CO (VIE:DOC) Have A Healthy Balance Sheet?

Jul 18

An Intrinsic Calculation For DO & CO Aktiengesellschaft (VIE:DOC) Suggests It's 38% Undervalued

Apr 03

What Kind Of Shareholders Own DO & CO Aktiengesellschaft (VIE:DOC)?

Feb 27

Revenue Downgrade: Here's What Analysts Forecast For DO & CO Aktiengesellschaft (VIE:DOC)

Jan 21

DO & CO's(VIE:DOC) Share Price Is Down 32% Over The Past Five Years.

Jan 17

Is DO & CO (VIE:DOC) Using Debt In A Risky Way?

Dec 21

Are Investors Undervaluing DO & CO Aktiengesellschaft (VIE:DOC) By 40%?

Nov 25

Winst- en omzetgroeiprognoses

WBAG:DOC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	2,432	127	154	209	4
3/31/2026	2,267	112	133	194	5
3/31/2025	2,148	92	102	171	2
6/30/2024	1,970	69	85	171	N/A
3/31/2024	1,819	66	103	180	N/A
12/31/2023	1,739	61	140	213	N/A
9/30/2023	1,632	55	120	176	N/A
6/30/2023	1,532	46	91	133	N/A
3/31/2023	1,419	34	77	114	N/A
12/31/2022	1,249	22	41	69	N/A
9/30/2022	1,086	17	43	66	N/A
6/30/2022	891	12	39	61	N/A
3/31/2022	705	11	50	67	N/A
12/31/2021	559	12	52	71	N/A
9/30/2021	428	7	27	48	N/A
6/30/2021	324	-14	25	52	N/A
3/31/2021	253	-38	-9	27	N/A
12/31/2020	365	-82	-34	28	N/A
9/30/2020	539	-77	-21	68	N/A
6/30/2020	720	-53	-21	76	N/A
3/31/2020	935	-25	7	103	N/A
12/31/2019	956	26	43	114	N/A
9/30/2019	922	25	20	73	N/A
6/30/2019	881	27	18	64	N/A
3/31/2019	848	26	13	55	N/A
12/31/2018	841	27	-10	33	N/A
9/30/2018	845	28	-7	46	N/A
6/30/2018	856	25	-36	30	N/A
3/31/2018	861	24	N/A	42	N/A
12/31/2017	848	19	N/A	60	N/A
9/30/2017	860	18	N/A	46	N/A
6/30/2017	879	19	N/A	37	N/A
3/31/2017	913	21	N/A	56	N/A
12/31/2016	943	25	N/A	46	N/A
9/30/2016	946	24	N/A	79	N/A
6/30/2016	942	28	N/A	107	N/A
3/31/2016	916	28	N/A	92	N/A
12/31/2015	912	30	N/A	84	N/A
9/30/2015	879	29	N/A	66	N/A
6/30/2015	839	33	N/A	67	N/A
3/31/2015	799	35	N/A	66	N/A
12/31/2014	751	35	N/A	58	N/A
9/30/2014	701	37	N/A	70	N/A
6/30/2014	664	30	N/A	42	N/A
3/31/2014	636	26	N/A	41	N/A
12/31/2013	617	24	N/A	33	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei DOC ( 18.4% per jaar) ligt boven de spaarquote ( 1.4% ).

Winst versus markt: De winst van DOC ( 18.4% per jaar) zal naar verwachting sneller groeien dan de Austrian markt ( 8.8% per jaar).

Hoge groeiwinsten: De winst van DOC zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van DOC ( 6.8% per jaar) zal naar verwachting sneller groeien dan de markt Austrian ( 0.8% per jaar).

Hoge groei-inkomsten: De omzet van DOC ( 6.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen DOC zal naar verwachting over 3 jaar hoog zijn ( 23.9 %)

DO & CO Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 8.8% to €186

Earnings Update: DO & CO Aktiengesellschaft (VIE:DOC) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Price target increased by 8.2% to €159

Price target increased by 16% to €147

Price target increased by 8.2% to €124

Price target increased to €113

Recent updates

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Does DO & CO (VIE:DOC) Deserve A Spot On Your Watchlist?

We Think DO & CO (VIE:DOC) Might Have The DNA Of A Multi-Bagger

Is DO & CO Aktiengesellschaft (VIE:DOC) Potentially Undervalued?

First quarter 2025 earnings released: EPS: €1.69 (vs €1.50 in 1Q 2024)

New minor risk - Share price stability

DO & CO Aktiengesellschaft's (VIE:DOC) Price In Tune With Earnings

Price target increased by 8.8% to €186

Earnings Update: DO & CO Aktiengesellschaft (VIE:DOC) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

DO & CO (VIE:DOC) Could Easily Take On More Debt

DO & CO (VIE:DOC) Shareholders Will Want The ROCE Trajectory To Continue

At €149, Is DO & CO Aktiengesellschaft (VIE:DOC) Worth Looking At Closely?

DO & CO (VIE:DOC) Could Easily Take On More Debt

We Think DO & CO's (VIE:DOC) Robust Earnings Are Conservative

Third quarter 2024 earnings released: EPS: €1.63 (vs €1.16 in 3Q 2023)

Shareholders Should Be Pleased With DO & CO Aktiengesellschaft's (VIE:DOC) Price

DO & CO Aktiengesellschaft, Annual General Meeting, Jul 25, 2024

At €133, Is It Time To Put DO & CO Aktiengesellschaft (VIE:DOC) On Your Watch List?

Second quarter 2024 earnings released: EPS: €1.90 (vs €1.10 in 2Q 2023)

Is There An Opportunity With DO & CO Aktiengesellschaft's (VIE:DOC) 48% Undervaluation?

The Returns At DO & CO (VIE:DOC) Aren't Growing

DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet

DO & CO Aktiengesellschaft Announces Executive Board Appointments

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

At €119, Is It Time To Put DO & CO Aktiengesellschaft (VIE:DOC) On Your Watch List?

DO & CO Aktiengesellschaft Approves Dividend for the Year 2022/2023 Year, Payable on 27 July 2023

DO & CO Aktiengesellschaft Announces Board Changes

Returns On Capital At DO & CO (VIE:DOC) Have Stalled

Price target increased by 8.2% to €159

New minor risk - Financial position

Is DO & CO Aktiengesellschaft (VIE:DOC) Trading At A 42% Discount?

Full year 2023 earnings released: EPS: €3.44 (vs €1.13 in FY 2022)

Price target increased by 16% to €147

Is It Time To Consider Buying DO & CO Aktiengesellschaft (VIE:DOC)?

An Intrinsic Calculation For DO & CO Aktiengesellschaft (VIE:DOC) Suggests It's 38% Undervalued

Price target increased by 8.2% to €124

Third quarter 2023 earnings released: EPS: €1.16 (vs €0.71 in 3Q 2022)

DO & CO Aktiengesellschaft announced that it has received €100 million in funding

DO & CO Aktiengesellschaft to Report First Half, 2024 Results on Nov 16, 2023

Price target increased to €113

Second quarter 2023 earnings released: EPS: €1.10 (vs €0.58 in 2Q 2022)

DO & CO Aktiengesellschaft to Report Fiscal Year 2023 Results on Jun 15, 2023

DO & CO's (VIE:DOC) Returns On Capital Not Reflecting Well On The Business

DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet

Is There Now An Opportunity In DO & CO Aktiengesellschaft (VIE:DOC)?

First quarter 2023 earnings released: EPS: €0.34 (vs €0.22 in 1Q 2022)

DO & CO Aktiengesellschaft to Report Q3, 2023 Results on Feb 16, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Does DO & CO (VIE:DOC) Have A Healthy Balance Sheet?

DO & CO Ordinary Shares to Be Deleted from Other OTC

Returns On Capital At DO & CO (VIE:DOC) Paint A Concerning Picture

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 13%

Price target increased to €101

DO & CO (VIE:DOC) Has A Pretty Healthy Balance Sheet

DO & CO Aktiengesellschaft, Annual General Meeting, Jul 14, 2022

Consensus forecasts updated

Why DO & CO's (VIE:DOC) Earnings Are Better Than They Seem

Second quarter 2022 earnings released: EPS €0.55 (vs €1.55 loss in 2Q 2021)

Capital Allocation Trends At DO & CO (VIE:DOC) Aren't Ideal

Price target increased to €88.06

First quarter 2022 earnings released: EPS €0.20 (vs €2.27 loss in 1Q 2021)

Does DO & CO (VIE:DOC) Have A Healthy Balance Sheet?

Price target increased to €85.40

Full year 2021 earnings released: €3.64 loss per share (vs €2.55 loss in FY 2020)